← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 1985First marketed drug
Jul 29, 1948First NDA
Jul 29, 1948Last known activity
Aug 31, 2019
Acquired by Glaxo Wellcome → GlaxoSmithKline on Jan 1, 1995
Timeline
1880s
- Jan 1, 1880
Burroughs Wellcome— Founded
1960s
- Jan 1, 1962
trimethoprim— NDA Organization
1990s
- Jan 1, 1995
Glaxo Wellcome— Acquired By
2000s
- Jan 1, 2000
GlaxoSmithKline— Now
Drugs by trial phase (4 distinct, 4 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Approved for
- Bipolar Disorder
- Colorectal Neoplasms
- Common Cold
- Depressive Disorder
- Epilepsies, Partial
- Epilepsy
- Epilepsy, Tonic-Clonic
- Eye Infections, Bacterial
- Fecal Incontinence
- HIV Infections
- Hodgkin Disease
- Hypersensitivity
- Infections
- Keratoconjunctivitis
- Lennox Gastaut Syndrome
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Musculoskeletal Manipulations
- Ovarian Neoplasms
- Pneumonia
- Pneumonia, Pneumocystis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Rhinitis, Allergic, Seasonal
- Seizures
- Skin Diseases
- Urinary Tract Infections
Marketed drugs (13)
Recent trials (4)
- NCT03897946CollaboratorPhase 4Aug 31, 2019
- NCT00185731CollaboratorPhase 2Apr 1, 2005
- NCT00002141Lead sponsorPhase 1Jul 1, 1994
- NCT00209352CollaboratorPhase 3Jun 1, 1985
Details
- Founded
- London, GB Jan 1, 1880
- First NDA
- Jul 29, 1948
- Last known activity
- Aug 31, 2019
Designations held
- Orphan drug
- Priority review